vs
Side-by-side financial comparison of Kymera Therapeutics, Inc. (KYMR) and TRANSACT TECHNOLOGIES INC (TACT). Click either name above to swap in a different company.
Kymera Therapeutics, Inc. is the larger business by last-quarter revenue ($11.5M vs $11.5M, roughly 1.0× TRANSACT TECHNOLOGIES INC). On growth, TRANSACT TECHNOLOGIES INC posted the faster year-over-year revenue change (11.9% vs -55.3%). TRANSACT TECHNOLOGIES INC produced more free cash flow last quarter ($589.0K vs $-60.6M). Over the past eight quarters, Kymera Therapeutics, Inc.'s revenue compounded faster (10.1% CAGR vs 3.5%).
Kymera Therapeutics is a clinical-stage biopharmaceutical company specialized in developing innovative targeted protein degradation therapies. It advances a diversified pipeline of drug candidates targeting previously undruggable proteins to address unmet medical needs in oncology, autoimmune and inflammatory diseases worldwide.
Roper Technologies, Inc. is a holding company that owns companies in the technology sector.
KYMR vs TACT — Head-to-Head
Income Statement — Q2 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $11.5M | $11.5M |
| Net Profit | $-76.6M | — |
| Gross Margin | — | 47.6% |
| Operating Margin | -736.8% | -10.1% |
| Net Margin | -667.6% | — |
| Revenue YoY | -55.3% | 11.9% |
| Net Profit YoY | -82.1% | — |
| EPS (diluted) | $-0.95 | $-0.11 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | — | $11.5M | ||
| Q3 25 | — | $13.2M | ||
| Q2 25 | $11.5M | $13.8M | ||
| Q1 25 | $22.1M | $13.1M | ||
| Q4 24 | $7.4M | $10.2M | ||
| Q3 24 | — | $10.9M | ||
| Q2 24 | $25.6M | $11.6M | ||
| Q1 24 | $10.3M | $10.7M |
| Q4 25 | — | — | ||
| Q3 25 | — | $15.0K | ||
| Q2 25 | $-76.6M | $-143.0K | ||
| Q1 25 | $-65.6M | $19.0K | ||
| Q4 24 | $-70.8M | — | ||
| Q3 24 | — | $-551.0K | ||
| Q2 24 | $-42.1M | $-319.0K | ||
| Q1 24 | $-48.6M | $-1.0M |
| Q4 25 | — | 47.6% | ||
| Q3 25 | — | 49.8% | ||
| Q2 25 | — | 48.2% | ||
| Q1 25 | — | 48.7% | ||
| Q4 24 | — | 44.2% | ||
| Q3 24 | — | 48.1% | ||
| Q2 24 | — | 52.7% | ||
| Q1 24 | — | 52.6% |
| Q4 25 | — | -10.1% | ||
| Q3 25 | — | 0.1% | ||
| Q2 25 | -736.8% | -1.9% | ||
| Q1 25 | -336.8% | -0.1% | ||
| Q4 24 | -1092.2% | -10.3% | ||
| Q3 24 | — | -7.7% | ||
| Q2 24 | -198.5% | -3.8% | ||
| Q1 24 | -562.2% | -12.2% |
| Q4 25 | — | — | ||
| Q3 25 | — | 0.1% | ||
| Q2 25 | -667.6% | -1.0% | ||
| Q1 25 | -296.7% | 0.1% | ||
| Q4 24 | -956.9% | — | ||
| Q3 24 | — | -5.1% | ||
| Q2 24 | -164.0% | -2.8% | ||
| Q1 24 | -472.0% | -9.7% |
| Q4 25 | — | $-0.11 | ||
| Q3 25 | — | $0.00 | ||
| Q2 25 | $-0.95 | $-0.01 | ||
| Q1 25 | $-0.82 | $0.00 | ||
| Q4 24 | $-0.89 | $-0.80 | ||
| Q3 24 | — | $-0.06 | ||
| Q2 24 | $-0.58 | $-0.03 | ||
| Q1 24 | $-0.69 | $-0.10 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $335.8M | $20.4M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $971.5M | $31.1M |
| Total Assets | $1.1B | $44.8M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | $20.4M | ||
| Q3 25 | — | $20.0M | ||
| Q2 25 | $335.8M | $17.7M | ||
| Q1 25 | $90.0M | $14.2M | ||
| Q4 24 | $120.3M | $14.4M | ||
| Q3 24 | — | $11.3M | ||
| Q2 24 | $67.6M | $11.1M | ||
| Q1 24 | $93.5M | $10.6M |
| Q4 25 | — | $31.1M | ||
| Q3 25 | — | $31.8M | ||
| Q2 25 | $971.5M | $31.3M | ||
| Q1 25 | $786.2M | $30.9M | ||
| Q4 24 | $835.6M | $30.6M | ||
| Q3 24 | — | $38.4M | ||
| Q2 24 | $684.9M | $38.5M | ||
| Q1 24 | $711.2M | $38.6M |
| Q4 25 | — | $44.8M | ||
| Q3 25 | — | $45.0M | ||
| Q2 25 | $1.1B | $44.5M | ||
| Q1 25 | $918.3M | $44.2M | ||
| Q4 24 | $978.0M | $44.0M | ||
| Q3 24 | — | $50.5M | ||
| Q2 24 | $826.0M | $50.4M | ||
| Q1 24 | $868.3M | $51.9M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-59.9M | $609.0K |
| Free Cash FlowOCF − Capex | $-60.6M | $589.0K |
| FCF MarginFCF / Revenue | -527.9% | 5.1% |
| Capex IntensityCapex / Revenue | 6.1% | 0.2% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | $-250.5M | $7.6M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | $609.0K | ||
| Q3 25 | — | $3.6M | ||
| Q2 25 | $-59.9M | $3.6M | ||
| Q1 25 | $-79.2M | $-161.0K | ||
| Q4 24 | $-61.8M | $2.4M | ||
| Q3 24 | — | $327.0K | ||
| Q2 24 | $-42.9M | $636.0K | ||
| Q1 24 | $-39.6M | $-1.5M |
| Q4 25 | — | $589.0K | ||
| Q3 25 | — | $3.6M | ||
| Q2 25 | $-60.6M | $3.6M | ||
| Q1 25 | $-79.6M | $-171.0K | ||
| Q4 24 | $-62.7M | $2.4M | ||
| Q3 24 | — | $259.0K | ||
| Q2 24 | $-47.6M | $499.0K | ||
| Q1 24 | $-47.0M | $-1.6M |
| Q4 25 | — | 5.1% | ||
| Q3 25 | — | 27.1% | ||
| Q2 25 | -527.9% | 25.9% | ||
| Q1 25 | -360.3% | -1.3% | ||
| Q4 24 | -848.3% | 23.2% | ||
| Q3 24 | — | 2.4% | ||
| Q2 24 | -185.7% | 4.3% | ||
| Q1 24 | -456.8% | -14.9% |
| Q4 25 | — | 0.2% | ||
| Q3 25 | — | 0.5% | ||
| Q2 25 | 6.1% | 0.1% | ||
| Q1 25 | 2.1% | 0.1% | ||
| Q4 24 | 12.7% | 0.1% | ||
| Q3 24 | — | 0.6% | ||
| Q2 24 | 18.3% | 1.2% | ||
| Q1 24 | 72.0% | 1.0% |
| Q4 25 | — | — | ||
| Q3 25 | — | 242.00× | ||
| Q2 25 | — | — | ||
| Q1 25 | — | -8.47× | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
